Dr. Dryden is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
401 E Chestnut St
Suite 310
Louisville, KY 40202Phone+1 502-584-8563Fax+1 502-562-6196
Clinical Expertise
- Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, Esophageal disease, Celiac disease, Esophagoscopy, Upper GI Endoscopy, Colon cancer, Medical device design
Education & Training
- University of LouisvillePhD, Microbiology and Immunology, 2016
- University of LouisvilleMSPH, Clinical Investigation, 2003
- Naval Medical Center (San Diego)Fellowship, Gastroenterology, 1995 - 1997
- Naval Medical Center (Portsmouth)Residency, Internal Medicine, 1992 - 1995
- University of Kentucky College of MedicineClass of 1992
Certifications & Licensure
- KY State Medical License 1998 - 2025
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Fellow (AGAF) American Gastroenterological Association, 2011
- Fellow (ASGE) American Society of Gastrointestinal Endoscopy, 2010
Clinical Trials
- Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis Start of enrollment: 2008 Mar 01
- Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis Start of enrollment: 2012 Feb 01
Publications & Presentations
PubMed
- 23 citationsNoninvasive Imaging of Colitis Using Multispectral Optoacoustic Tomography.Neal Bhutiani, William E. Grizzle, Susan Galandiuk, Denis Otali, Gerald W. Dryden
Journal of Nuclear Medicine. 2017-06-01 - 291 citationsTargeted Drug Delivery to Intestinal Macrophages by Bioactive Nanovesicles Released from GrapefruitBaomei Wang, Xiaoying Zhuang, Zhongbin Deng, Hong Jiang, Jingyao Mu
Molecular Therapy. 2014-03-01 - 75 citationsRandomized, double‐blind, placebo‐controlled trial of the oral interleukin‐12/23 inhibitor apilimod mesylate for treatment of active Crohn's diseaseBruce E. Sands, Eric W. Jacobson, Thomas Sylwestrowicz, Ziad Younes, Gerald W. Dryden
Inflammatory Bowel Diseases. 2010-07-01
Press Mentions
- UofL and Robley Rex VA Medical Center Partnership Leads to New State-of-the-Art Multiphoton Microscopes for Exposure StudiesNovember 22nd, 2022
- Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease PatientsJuly 26th, 2021
- uBiome Launches Research Partnership with University of Louisville Physicians to Investigate the Microbiome as a Predictor of Clinical Response to IBD TherapiesMarch 7th, 2019
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: